Sahil Khanna
Gastroenterology · Rochester, MNNPI 1699939314
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $185,682 of the $241,558 with a category attached, or 76.9%. 12 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 44.5% of the total. Reporting peaked in 2023 at $84,453 and has fallen 65.2% since, to $29,354 in 2025. Among gastroenterology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $1948.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$107K
- Ferring Pharmaceuticals AS$38K
- Ferring International Center SA$30K
- Takeda Pharmaceuticals U.S.A., Inc.$28K
- Shire North American Group Inc$22K
- Aimmune Therapeutics, Inc.$5K
- plus $10K from 6 others
Across 25 payments — averaging $38,973 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$820K
- Ferring Pharmaceuticals AS$123K
- Rebiotix Inc.$27K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
What the payments were for
- Consulting fees$185,68277%
- Speaking & faculty fees$32,73514%
- Travel & lodging$20,3218%
- Food & beverage$2,1421%
- Education$6790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 80 | $107,442 |
| Ferring Pharmaceuticals AS | 15 | $38,053 |
| Ferring International Center SA | 14 | $30,434 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $28,200 |
| Shire North American Group Inc | 3 | $22,200 |
| Aimmune Therapeutics, Inc. | 2 | $5,228 |
| Ferring International Pharmascience Center US | 1 | $3,871 |
| Ferring Inc. | 1 | $2,790 |
| GSK | 1 | $2,030 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,000 |
| Johnson & Johnson | 2 | $223 |
| AstraZeneca | 1 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$241,558 in reported general payments places this provider in the 95th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 45 | $6,734 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Rochester
- John KisielRochester$856K
- Christopher GostoutRochester$299K
- Edward LoftusRochester$282K
- Alina AllenRochester$277K
- Todd BaronRochester$270K
- Joseph MurrayRochester$234K
- Andres AcostaRochester$224K
- David LarsonRochester$142K
- Ibrahim HanounehRochester$104K
- Bret PetersenRochester$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.